A double blind, randomised, placebo controlled study investigating the efficacy of roflumilast in reducing number of acute events in patients with chronic fibrotic sarcoidosis
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Roflumilast (Primary)
- Indications Sarcoidosis
- Focus Therapeutic Use
- 13 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society